

All Your Ingredients In One Magazine

Ingredients

SOUTH ASIA


A Saffron Media Publication
Vol. 19, Issue 13, Pages-44



SPECTRUM
Ingredients Pvt. Ltd.

Spectrum Ingredients Pvt. Ltd. is a dynamic and forward-thinking company dedicated to supplier of high-quality fragrance and flavor ingredients. With a deep commitment to excellence, we serve a diverse range of industries including personal care, home care, fine fragrance, pharmaceuticals and food & beverage.

- ❖ **Speciality Chemicals**
- ❖ **Aroma Ingredients**
- ❖ **Natural Oils**
- ❖ **Pharmaceuticals Raw Materials**
- ❖ **Fragrance & Flavours**



Spectrum Ingredients Pvt. Ltd.

Office No. 1101, 11th Floor, Kamla Hub, N. S. Road No. 1, CTS No. 35,

Near Gagandeep, J.V.P.D. Scheme, Juhu, Vile Parle (West), Mumbai - 400 049.

Tel: +91-22-2670 8610 • Mob: +91 86570 33989 • Email: enquiry@spectruming.com

www.spectruming.com

Oncology APIs represent one of fastest-growing segments

DR. SANJAY AGRAWAL

THE pharmaceutical industry is a highly regulated, research-driven, and globally interconnected sector responsible for developing, manufacturing, and distributing medicines. At the heart of every medicinal product lies the Active Pharmaceutical Ingredient (API) - the biologically active component that produces the intended therapeutic effect. Whether in a tablet, capsule, injectable, or topical formulation, the API is the core substance that treats, cures, mitigates, or prevents disease.

This article provides an in-depth understanding of APIs, their types, manufacturing processes, regulatory framework, and a comprehensive overview of the global API market landscape.

What is an Active Pharmaceutical Ingredient (API)?

An Active Pharmaceutical Ingredient (API) is the primary component in a pharmaceutical drug responsible for its pharmacological activity. In a finished dosage form (FDF), the API is combined with excipients - substances that serve as carriers or stabilisers but do not have therapeutic effects.

For example:

- In paracetamol tablets, paracetamol itself is the API.
- In insulin injections, insulin is the API.

APIs are used in both branded and generic medicines and can be synthesised chemically, derived from biological sources, or produced using biotechnological processes.

Types of APIs

APIs are broadly categorised based on their source and method of production:

1. Synthetic APIs

These are produced through chemical synthesis using organic and inorganic chemical reactions. They represent a large portion of small-molecule drugs used in treatments for cardiovascular diseases, infections, and pain management.

2. Biotech APIs (Biological APIs)

These are derived from biological processes and include monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies. Biotech APIs are more complex and sensitive compared to synthetic APIs.

3. Highly Potent APIs (HPAPIs)

HPAPIs are compounds effective at very low doses and require specialised manufacturing facilities due to their high pharmacological potency. They are widely used in oncology and targeted therapies.

API Manufacturing Process

The API manufacturing process is highly technical and regulated. It typically involves:

1. Research and Development

The discovery and optimisation of the active molecule through preclinical research and clinical trials.

2. Process Development

Optimisation of synthesis routes for scalability, cost efficiency, and purity.

3. Production

Large-scale manufacturing in compliance with Good Manufacturing Practices (GMP).

4. Purification and Crystallisation

Removal of impurities to meet pharmacopeial standards.

5. Quality Control and Testing

Ensuring compliance with regulatory specifications for identity, purity, strength, and stability.

Regulatory Framework for APIs

APIs are subject to strict regulatory oversight globally. Regulatory authorities ensure safety, quality, and efficacy.

Key regulatory bodies include:

- U.S. Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- Central Drugs Standard Control Organization (CDSCO)
- Pharmaceuticals and Medical Devices Agency (PMDA)

Manufacturers must submit a Drug Master File (DMF) containing detailed information on API manufacturing, controls, and stability data.

Compliance with:

- Good Manufacturing Practices (GMP)
- International Council for Harmonisation (ICH) guidelines

- Pharmacopoeial standards (USP, EP, IP) is mandatory for global trade.

Global API Market Overview

The API market is a critical segment of the pharmaceutical supply chain and has experienced significant growth over the past decade.

Market Size and Growth

The global API market has expanded rapidly due to:

- Rising prevalence of chronic diseases (diabetes, cardiovascular diseases, cancer)
- Growing geriatric population
- Increased demand for generic medicines
- Expansion of biopharmaceuticals
- Covid-19 pandemic impact on drug demand


The market is projected to grow at a strong compound annual growth rate (CAGR), driven particularly by biotech APIs and oncology drugs.

Segmentation of the API Market

By Type:



CONTINUED ON p20 ▶



**Medisearch Laboratories
(Bombay) Pvt. Ltd.**


**STABILIZED OXYCHLORO
COMPLEX (HPLR)**

Produced in **Technical collaboration**
with ERC Biolabs (UK).

Meets the stringent
European Pharmacopeia Criteria.

COA, MSDS, MOA and
European PET data available.

Exported to various countries including EU.



Contact: medisearchsoc@gmail.com

API market undergoing structural transformation

CONTINUED FROM p19▶

- Synthetic APIs
- Biotech APIs

Biotech APIs are growing faster due to increased demand for biologics and personalised medicine.

By Manufacturer Type:

- Captive APIs (manufactured in-house by pharmaceutical companies)
- Merchant APIs (manufactured by third-party suppliers)

Merchant API manufacturers play a crucial role in the global generic drug supply chain.

By Therapeutic Application:

- Cardiovascular diseases
- Oncology
- Central nervous system disorders
- Anti-infectives
- Respiratory diseases
- Diabetes

Oncology APIs represent one of the fastest-growing therapeutic segments due to increasing cancer prevalence.

Major API Manufacturing Countries

The API market is geographically concentrated, with several countries dominating production:

India

India is one of the largest producers of generic APIs globally and supplies a significant portion of the world's generic drug requirements. It is often referred to as the "pharmacy of the world."

China

China is a major supplier of key starting materials (KSMs) and bulk APIs. Many global pharmaceutical companies depend on Chinese raw materials.

United States

The U.S. has strong biotech API production and focuses on innovation-driven, high-value molecules.

Germany and Switzerland

These countries are leaders in high-quality and specialty API manufacturing, particularly in biologics.

API Market Trends

The API market is undergoing structural transformation due to scientific advancements, regulatory changes, and evolving global healthcare needs. Several major trends are shaping its future direction.

One of the most significant trends is the shift toward biologics. Biotech APIs are growing at a faster pace than traditional synthetic APIs

due to increasing demand for monoclonal antibodies, gene therapies, recombinant proteins, and biosimilars. The rising prevalence of cancer, autoimmune diseases, and rare disorders has accelerated investment in biological drugs. Biologic APIs require complex manufacturing processes such as cell culture and fermentation, along with advanced quality controls and cold chain logistics, making them more capital-intensive but also higher in value.


Another important trend is supply chain diversification. The Covid-19 pandemic revealed vulnerabilities in global pharmaceutical supply chains, particularly over-dependence on limited geographic regions for raw materials and intermediates. In response, governments and pharmaceutical companies are investing in domestic API production, dual sourcing strategies, and strategic stockpiling of essential medicines. Policies supporting self-reliance and local man-

ufacturing are becoming increasingly common across major economies.

implemented to reduce environmental impact and ensure long-term regulatory compliance. Digitalisation and automation are transforming API production processes. Industry 4.0 technologies such as artificial intelligence, real-time quality monitoring, predictive maintenance, and electronic batch records are improving operational efficiency and regulatory compliance. Digital tools enhance traceability, reduce human error, and optimise production yields. As regulatory requirements become more stringent, digital systems help manufacturers maintain accurate documentation and ensure data integrity.

Challenges in the API Market

Despite its growth potential, the API industry faces several structural and operational challenges that influence profitability and sustainability.



ufacturing are becoming increasingly common across major economies.

The demand for highly potent APIs (HPAPIs) is also rising rapidly, particularly in oncology and targeted therapies. HPAPIs are effective at very low doses and require specialised containment facilities and safety protocols during manufacturing. The growth of antibody-drug conjugates (ADCs) and precision medicine is further fueling demand for such potent molecules. This segment is expected to grow faster than conventional API categories due to its role in advanced therapeutic areas.

Sustainability and green chemistry are becoming critical considerations in API manufacturing. Traditional chemical synthesis often involves hazardous solvents, high energy consumption, and significant waste generation. Stricter environmental regulations, especially in Asia and Europe, are pushing manufacturers to adopt eco-friendly production methods. Continuous manufacturing, solvent recovery systems, energy-efficient technologies, and waste minimisation strategies are increasingly being

Regulatory compliance remains one of the most significant challenges. API manufacturers must adhere to Good Manufacturing Practices (GMP), International Council for Harmonisation (ICH) guidelines, and stringent documentation standards. Inspections by international regulatory authorities can result in warning letters, import alerts, or plant shutdowns if deficiencies are found. Maintaining compliance requires continuous investment in infrastructure, training, and quality management systems, which can be particularly burdensome for smaller manufacturers.

Pricing pressure is another major concern, especially in the generic API segment. Intense competition among manufacturers, tender-based procurement systems, and consolidation among pharmaceutical buyers have led to shrinking profit margins. Companies are often forced to compete primarily on cost, making operational efficiency critical for survival. This environment has encouraged mergers, acquisitions, and strategic alliances within the API sector.

CONTINUED ON p25▶

Increasing shift toward preventive healthcare

CONTINUED FROM p24▶

The market is expected to grow at a CAGR of 7.1% from 2025 to 2030. Biologics & Biosimilars (Large Molecules) is the most lucrative molecule segment registering the fastest growth during the forecast period. Country-wise, India is expected to register the highest CAGR from 2025 to 2030. Asia Pacific is the fastest growing regional market and is projected to reach US\$503,932.0 million by 2030.

Focus on Preventive Healthcare and Vaccination

As global populations age and lifestyle-related diseases rise, the pharmaceutical industry will increasingly shift toward preventive healthcare. Preventive strategies reduce long-term healthcare costs and enhance population health. Future areas of focus include: Expanded vaccine pipelines for emerging pathogens, Development of vaccines for chronic diseases such as cancers, Growth of nutraceuticals and immune-boosting supplements, Preventive biologics and monoclonal antibodies, Screening tools that detect diseases at early stages, Pharma companies will actively collaborate with governments and

public health agencies to strengthen immunisation programs and pandemic preparedness.

The Asia Pacific region, with its blend of developing and developed economies, is experiencing rising healthcare expenditure that is expected

In parallel, the pharmaceutical industry in Asia Pacific has made notable strides in recent years

to drive substantial growth in the pharmaceutical market. Demographic trends—particularly a rapidly aging population—along with increasing awareness of health conditions such as dry eye syndrome, diabetes, and cardiovascular disease, are fueling demand for a broad range of pharmaceutical products. As healthcare needs evolve, both public and private sectors are investing more to improve treatment accessibility and strengthen medical infrastructure across the region.

In parallel, the pharmaceutical industry in Asia

Pacific has made notable strides in recent years, guided by a commitment to enhancing productivity and expanding research and development capabilities. Countries including China, Japan, India, and South Korea are at the forefront of these advancements, leveraging strong scientific talent and supportive government policies to accelerate biopharmaceutical innovation. The adoption of cutting-edge health technologies—such as artificial intelligence, digital health platforms, and advanced data analytics—is reshaping drug discovery, optimising clinical trials, and improving supply chain efficiency.

Together, these factors position the Asia Pacific pharmaceutical industry for sustained expansion. The region's demographic momentum, coupled with continuous technological progress and growing healthcare investment, will reinforce its role as a major contributor to global pharmaceutical development in the years ahead. ○

(The author is professor, Amity University Madhya Pradesh, Gwalior. He can be reached at nmishra1@gva.amity.edu)

Relying on limited number of suppliers for KSMs

CONTINUED FROM p20▶

Environmental regulations pose additional challenges. API manufacturing involves chemical reactions that may produce hazardous waste, solvent emissions, and wastewater discharge. Compliance with environmental standards requires investment in effluent treatment plants, air emission control systems, and sustainable waste management practices. Non-compliance can lead to heavy penalties, plant closures, and reputational damage.

Raw material dependency creates supply chain vulnerabilities. Many API manufacturers rely on a limited number of suppliers for key starting materials and intermediates. Disruptions caused by geopolitical tensions, trade restrictions, natural disasters, or pandemics can severely impact production schedules and global drug availability. As a result, companies are increasingly seeking to diversify suppliers and localise production where feasible.

Intellectual property (IP) dynamics also influence the API market. Patent expirations open opportunities for generic API production but simultaneously intensify competition. Patent litigation, data exclusivity issues, and regulatory complexities can delay market entry. For innovative APIs, strong IP protection supports profitability and investment in research, whereas for generics, patent cliffs create rapid shifts in demand cycles.

Role of APIs in Generic vs Branded Drugs

In branded drugs, APIs are often patented and developed through extensive R&D investment. In generic drugs, once patents expire, other manufacturers can produce the same API, provided they meet regulatory standards.

The generic API market contributes significantly to affordable healthcare worldwide. Countries like India dominate this segment due to cost-effective manufacturing and strong regulatory compliance for export markets.

Future Outlook of the API Industry

The API market is expected to witness sustained growth due to:

- Rising healthcare expenditure
- Expansion of biosimilars
- Increased outsourcing to contract development and manufacturing organisations (CDMOs)
- Growth in emerging markets
- Technological advancements in continuous manufacturing

Government initiatives in countries like India promoting domestic API production through production-linked incentive (PLI) schemes further strengthen the industry's future outlook. Moreover, strategic partnerships, mergers, and acquisitions are reshaping the competitive landscape.

Moreover, strategic partnerships, mergers, and acquisitions are reshaping the competitive landscape

Conclusion

The Active Pharmaceutical Ingredient (API) forms the foundation of every pharmaceutical product. It is the core substance responsible for therapeutic efficacy and plays a pivotal role in both branded and generic drug manufacturing.

The global API market is dynamic, competitive, and innovation-driven. With increasing chronic disease burden, growing demand for biologics, and global healthcare expansion, APIs remain central to pharmaceutical development.

However, the industry must address regulatory challenges, supply chain vulnerabilities, pricing pressures, and environmental concerns to ensure sustainable growth.

As pharmaceutical technologies evolve and personalised medicine advances, the role of APIs—particularly biotech and highly potent molecules—will become even more significant in shaping the future of global healthcare. ○

(The author is a leading pharmaceutical consultant)